CN103059000A - Novel omeprazole compound and pharmaceutical composition thereof - Google Patents
Novel omeprazole compound and pharmaceutical composition thereof Download PDFInfo
- Publication number
- CN103059000A CN103059000A CN2013100348956A CN201310034895A CN103059000A CN 103059000 A CN103059000 A CN 103059000A CN 2013100348956 A CN2013100348956 A CN 2013100348956A CN 201310034895 A CN201310034895 A CN 201310034895A CN 103059000 A CN103059000 A CN 103059000A
- Authority
- CN
- China
- Prior art keywords
- sodium
- omeprazole
- pharmaceutical composition
- parts
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a novel omeprazole compound. The purity of the novel omeprazole compound reaches more than 99.8%. Meanwhile, the invention also discloses a pharmaceutical composition of the novel omeprazole compound. The pharmaceutical composition comprises the following components in parts by weight: 62-90 parts of omeprazole sodium, 10-25 parts of sodium glutamate, 1-4 parts of sodium tartrate and 7-12 parts of vitamin C. According to the pharmaceutical composition of the novel omeprazole compound, a synergistic effect is generated between sodium glutamate and sodium tartrate, so that the stability of omeprazole sodium is remarkably improved, and the pharmaceutical composition has important significance for omeprazole sodium in clinical popularization and application.
Description
Technical field
The present invention relates to a kind of compound and pharmaceutical composition thereof that is used for the treatment of gastric ulcer, especially a kind of novel omeprazole sodium compound and pharmaceutical composition thereof.
Background technology
Omeprazole Sodium, its chemistry 5-methoxyl group-2-{ [(4-methoxyl group-3,5-dimethyl-2-pyridyl)-methyl]-sulfinyl } by name-1H-benzoglyoxaline sodium-hydrate is the hydrochloric acid in gastric juice proton pump inhibitor that is widely used in recent years treating digestive tract ulcer.The purity of the Omeprazole Sodium that prior art obtains is generally lower, causes the preparation stability of Omeprazole Sodium to decline to a great extent, and has affected its clinical application.The less stable of existing Omeprazole Sodium, relatively more responsive to light, heat, oxygen etc., especially under acidic conditions, its chemical structure can be destroyed.And the untoward reactions such as feeling sick often appears in the existing patient who takes the Omeprazole Sodium medicine, diarrhoea, stomachache, dizziness, headache, seriously restricted applying of Omeprazole Sodium.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art part and provide a kind of purity higher novel omeprazole sodium compound.Simultaneously, the present invention also provides the pharmaceutical composition of the omeprazole sodium compound that a kind of stability is significantly improved.
For achieving the above object, the technical scheme that the present invention takes is: a kind of novel omeprazole sodium compound, and the structural formula of described compound is:
Described omeprazole sodium compound adopts following methods to be prepared from: the Omeprazole Sodium crude product is water-soluble, regulate pH value to 6.0 ~ 7.2, the solid that collection is separated out, with the solid that obtains with dissolve with ethanol after, through macroporous adsorbent resin eluent ethyl acetate purifying, collect ethyl acetate and regulate pH for alkaline, collect the solid of separating out, obtain omeprazole sodium compound;
The purity of described omeprazole sodium compound is greater than 99.8%.
In addition, the invention provides the pharmaceutical composition of the novel omeprazole sodium compound that a kind of stability is significantly improved, described pharmaceutical composition comprises the component of following weight part: 62 ~ 90 parts of Omeprazole Sodiums, 10 ~ 25 parts of Sodium Glutamates, 1 ~ 4 part of sodium tartrate, 7 ~ 12 parts of vitamins Cs.The contriver finds that the Sodium Glutamate that contains in the described pharmaceutical composition and sodium tartrate produce synergy, but the stability of Effective Raise Omeprazole Sodium.
As the preferred implementation of the pharmaceutical composition of novel omeprazole sodium compound of the present invention, the mass ratio of described Sodium Glutamate and sodium tartrate is 8 ~ 10:1.When the mass ratio of described Sodium Glutamate and sodium tartrate is 8 ~ 10:1, more remarkable to the raising of the stability of Omeprazole Sodium.More preferably, the mass ratio of described Sodium Glutamate and sodium tartrate is 9:1, and this moment is the most remarkable to the raising of the stability of Omeprazole Sodium.
As the preferred implementation of the pharmaceutical composition of novel omeprazole sodium compound of the present invention, described pharmaceutical composition comprises the component of following weight part: 70 parts of Omeprazole Sodiums, 18 parts of Sodium Glutamates, 2 parts of sodium tartrates, 10 parts of vitamins Cs.
As the preferred implementation of the pharmaceutical composition of novel omeprazole sodium compound of the present invention, described Omeprazole Sodium and Sodium Glutamate, sodium tartrate and ascorbic quality and mass ratio be 2 ~ 4:1.The contriver is unexpected to be found, when Omeprazole Sodium and Sodium Glutamate, sodium tartrate and ascorbic quality and mass ratio when being 2 ~ 4:1, can significantly reduce the untoward reaction probability of Omeprazole Sodium, alleviate patient's misery.More preferably, described Omeprazole Sodium and Sodium Glutamate, sodium tartrate and ascorbic quality and mass ratio be 3:1, more remarkable to the reduction of the untoward reaction probability of Omeprazole Sodium.
As the preferred implementation of the pharmaceutical composition of novel omeprazole sodium compound of the present invention, described pharmaceutical composition comprises the component of following weight part: 90 parts of Omeprazole Sodiums, 18 parts of Sodium Glutamates, 2 parts of sodium tartrates, 10 parts of vitamins Cs.
As the preferred implementation of the pharmaceutical composition of novel omeprazole sodium compound of the present invention, described pharmaceutical composition is injection liquid, lyophilized injectable powder, oral preparations or sprays.
At last, the present invention also provides the application of novel omeprazole sodium compound described above in preparation treatment Gastric Ulcer Treatment.
The macroporous adsorbent resin wash-out purifying gained of novel omeprazole sodium compound of the present invention, the purity of gained omeprazole sodium compound is up to more than 99.8%.The pharmaceutical composition of omeprazole sodium compound of the present invention, Sodium Glutamate wherein and sodium tartrate produce synergy, have significantly improved the stability of Omeprazole Sodium, for Omeprazole Sodium clinically apply important meaning.
Embodiment
For the purpose, technical solutions and advantages of the present invention better are described, the invention will be further described below in conjunction with specific embodiment.
Embodiment 1
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are injection liquid, and described injection liquid is prepared from by following steps:
(1) gets 400 milliliters of waters for injection and be placed in the container, then add Sodium Glutamate 250mg, sodium tartrate 40mg and vitamins C 70mg, add activated carbon after the dissolving, filter, form solution A;
(2) get 200 milliliters of waters for injection and be placed in another container, slowly add Omeprazole Sodium 900mg, be stirred to described Omeprazole Sodium and dissolve fully, form solution B;
(3) solution B is joined in the solution A, and inject water to 1000ml, again add activated carbon, filter after stirring, form solution C;
(4) content of Omeprazole Sodium in the detection solution C can be packed after the smart filter of qualified solution process, embedding, the sterilization, forms the drug combination injection of Omeprazole Sodium.
Embodiment 2
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are injection liquid, and described injection liquid is prepared from by following steps:
(1) gets 400 milliliters of waters for injection and be placed in the container, then add Sodium Glutamate 100mg, sodium tartrate 10mg and vitamins C 120mg, add activated carbon after the dissolving, filter, form solution A;
(2) get 100 milliliters of waters for injection and be placed in another container, slowly add Omeprazole Sodium 620mg, be stirred to described Omeprazole Sodium and dissolve fully, form solution B;
(3) solution B is joined in the solution A, and inject water to 1000ml, again add activated carbon, filter after stirring, form solution C;
(4) content of Omeprazole Sodium in the detection solution C can be packed after the smart filter of qualified solution process, embedding, the sterilization, forms the drug combination injection of Omeprazole Sodium.
Embodiment 3
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are injection liquid, and described injection liquid is prepared from by following steps:
(1) gets 400 milliliters of waters for injection and be placed in the container, then add Sodium Glutamate 180mg, sodium tartrate 20mg and vitamins C 100mg, add activated carbon after the dissolving, filter, form solution A;
(2) get 150 milliliters of waters for injection and be placed in another container, slowly add Omeprazole Sodium 700mg, be stirred to described Omeprazole Sodium and dissolve fully, form solution B;
(3) solution B is joined in the solution A, and inject water to 1000ml, again add activated carbon, filter after stirring, form solution C;
(4) content of Omeprazole Sodium in the detection solution C can be packed after the smart filter of qualified solution process, embedding, the sterilization, forms the drug combination injection of Omeprazole Sodium.
Embodiment 4
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are injection liquid, and described injection liquid is prepared from by following steps:
(1) gets 400 milliliters of waters for injection and be placed in the container, then add Sodium Glutamate 240mg, sodium tartrate 30mg and vitamins C 90mg, add activated carbon after the dissolving, filter, form solution A;
(2) get 100 milliliters of waters for injection and be placed in another container, slowly add Omeprazole Sodium 720mg, be stirred to described Omeprazole Sodium and dissolve fully, form solution B;
(3) solution B is joined in the solution A, and inject water to 1000ml, again add activated carbon, filter after stirring, form solution C;
(4) content of Omeprazole Sodium in the detection solution C can be packed after the smart filter of qualified solution process, embedding, the sterilization, forms the drug combination injection of Omeprazole Sodium.
Embodiment 5
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are injection liquid, and described injection liquid is prepared from by following steps:
(1) gets 400 milliliters of waters for injection and be placed in the container, then add Sodium Glutamate 180mg, sodium tartrate 20mg and vitamins C 100mg, add activated carbon after the dissolving, filter, form solution A;
(2) get 300 milliliters of waters for injection and be placed in another container, slowly add Omeprazole Sodium 900mg, be stirred to described Omeprazole Sodium and dissolve fully, form solution B;
(3) solution B is joined in the solution A, and inject water to 1000ml, again add activated carbon, filter after stirring, form solution C;
(4) content of Omeprazole Sodium in the detection solution C can be packed after the smart filter of qualified solution process, embedding, the sterilization, forms the drug combination injection of Omeprazole Sodium.
Embodiment 6
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are lyophilized injectable powder, and described lyophilized injectable powder is prepared from by following methods:
(1) with Omeprazole Sodium 900mg, Sodium Glutamate 100mg, sodium tartrate 40mg and vitamins C 120mg
Be dissolved in the water for injection, add water to 1000ml, stir;
(2) add gac in the solution after step (1) stirs and stir, regulate pH=6.5 with sodium hydroxide, decarburization is filtered by the smart filter of film, can;
(3) the good solution of can in the step (2) is cooled to rapidly in freeze drier freezes, kept freezing 3-5 hour 40 ℃ to-30 ℃ of ﹣, vacuumize, vacuum freezedrying 24 hours, vacuum moulding lid rolls lid, namely gets the medicinal composition freezing-dried powder injection of Omeprazole Sodium.
Embodiment 7
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are lyophilized injectable powder, and described lyophilized injectable powder is prepared from by following methods:
(1) Omeprazole Sodium 620mg, Sodium Glutamate 250mg, sodium tartrate 10mg and vitamins C 70mg are dissolved in the water for injection, add water to 1000ml, stir;
(2) add gac in the solution after step (1) stirs and stir, regulate pH=6.5 with sodium hydroxide, decarburization is filtered by the smart filter of film, can;
(3) the good solution of can in the step (2) is cooled to rapidly in freeze drier freezes, kept freezing 3-5 hour 40 ℃ to-30 ℃ of ﹣, vacuumize, vacuum freezedrying 24 hours, vacuum moulding lid rolls lid, namely gets the medicinal composition freezing-dried powder injection of Omeprazole Sodium.
Embodiment 8
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are lyophilized injectable powder, and described lyophilized injectable powder is prepared from by following methods:
(1) Omeprazole Sodium 750mg, Sodium Glutamate 160mg, sodium tartrate 20mg and vitamins C 70mg are dissolved in the water for injection, add water to 1000ml, stir;
(2) add gac in the solution after step (1) stirs and stir, regulate pH=6.5 with sodium hydroxide, decarburization is filtered by the smart filter of film, can;
(3) the good solution of can in the step (2) is cooled to rapidly in freeze drier freezes, kept freezing 3-5 hour 40 ℃ to-30 ℃ of ﹣, vacuumize, vacuum freezedrying 24 hours, vacuum moulding lid rolls lid, namely gets the medicinal composition freezing-dried powder injection of Omeprazole Sodium.
Embodiment 9
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are lyophilized injectable powder, and described lyophilized injectable powder is prepared from by following methods:
(1) Omeprazole Sodium 900mg, Sodium Glutamate 180mg, sodium tartrate 20mg and vitamins C 100mg are dissolved in the water for injection, add water to 1000ml, stir;
(2) add gac in the solution after step (1) stirs and stir, regulate pH=6.5 with sodium hydroxide, decarburization is filtered by the smart filter of film, can;
(3) the good solution of can in the step (2) is cooled to rapidly in freeze drier freezes, kept freezing 3-5 hour 40 ℃ to-30 ℃ of ﹣, vacuumize, vacuum freezedrying 24 hours, vacuum moulding lid rolls lid, namely gets the medicinal composition freezing-dried powder injection of Omeprazole Sodium.
Embodiment 10
A kind of pharmaceutical composition of omeprazole sodium compound, described pharmaceutical composition are lyophilized injectable powder, and described lyophilized injectable powder is prepared from by following methods:
(1) Omeprazole Sodium 800mg, Sodium Glutamate 240mg, sodium tartrate 40mg and vitamins C 120mg are dissolved in the water for injection, add water to 1000ml, stir;
(2) add gac in the solution after step (1) stirs and stir, regulate pH=6.5 with sodium hydroxide, decarburization is filtered by the smart filter of film, can;
(3) the good solution of can in the step (2) is cooled to rapidly in freeze drier freezes, kept freezing 3-5 hour 40 ℃ to-30 ℃ of ﹣, vacuumize, vacuum freezedrying 24 hours, vacuum moulding lid rolls lid, namely gets the medicinal composition freezing-dried powder injection of Omeprazole Sodium.
Embodiment 11
1, the injection liquid stability under high temperature, high humidity and high light respectively
Experimental group, control group and blank group are set respectively, and experimental group 1-5 adopts respectively embodiment 1-5 gained ao meilazole sodium injection liquid.
In the injection liquid that control group 1 adopts, every 1000ml injection liquid contains Omeprazole Sodium 900mg, Sodium Glutamate 180mg, vitamins C 100mg, and surplus is water for injection.
In the injection liquid that control group 2 adopts, every 1000ml injection liquid contains Omeprazole Sodium 900mg, sodium tartrate 20mg, vitamins C 100mg, and surplus is water for injection.
In the injection liquid that control group 3 adopts, every 1000ml injection liquid contains Omeprazole Sodium 900mg, vitamins C 100mg, and surplus is water for injection.
In the injection liquid that blank group adopts, every 1000ml injection liquid contains Omeprazole Sodium 900mg, and surplus is water for injection.
The injection liquid of control group and blank group all adopts the method among the embodiment 1-5 to be prepared from.
Experimental group, control group and blank group injection liquid all 60 ℃ of lower placements one month, are detected the related substance that Omeprazole Sodium decomposes, the results are shown in Table 1.
The injection liquid of experimental group, control group and blank group was all placed one month under relative humidity RH is 75 ± 5% condition, detected the related substance that Omeprazole Sodium decomposes, the results are shown in Table 1.
The injection liquid of experimental group, control group and blank group was shone one month under the high light that equal illumination is (4500 ± 500) LX, detect the related substance that Omeprazole Sodium decomposes, the results are shown in Table 1.
The stability of table 1 injection liquid under high temperature, high humidity and high light
As seen from Table 1, Sodium Glutamate and sodium tartrate have produced synergy, the acting in conjunction of the two can significantly improve the stability under ao meilazole sodium injection liquid high temperature, high humidity and the high light, especially when the mass ratio of Sodium Glutamate and sodium tartrate is 8 ~ 10:1, improve more remarkable to the stability of ao meilazole sodium injection liquid under high temperature, high humidity and high light.
2, the lyophilized injectable powder stability under high temperature, high humidity and high light respectively
Experimental group, control group and blank group are set respectively, and experimental group 1-5 adopts respectively the omeprazole freeze-dried powder injection of embodiment 6-10 gained.
The lyophilized injectable powder that control group 1 adopts is prepared from according to the method among the embodiment 6-10 by Omeprazole Sodium 900mg, Sodium Glutamate 180mg and vitamins C 100mg.
The lyophilized injectable powder that control group 2 adopts is prepared from according to the method among the embodiment 6-10 by Omeprazole Sodium 900mg, sodium tartrate 20mg and vitamins C 100mg.
The lyophilized injectable powder that control group 3 adopts is prepared from according to the method among the embodiment 6-10 by Omeprazole Sodium 900mg and vitamins C 100mg.
The lyophilized injectable powder that blank group adopts is prepared from according to the method among the embodiment 6-10 by Omeprazole Sodium 900mg.
Experimental group, control group and blank group lyophilized injectable powder all 60 ℃ of lower placements one month, are detected the related substance that Omeprazole Sodium decomposes, the results are shown in Table 2.
The lyophilized injectable powder of experimental group, control group and blank group was all placed one month under relative humidity RH is 75 ± 5% condition, detected the related substance that Omeprazole Sodium decomposes, the results are shown in Table 2.
The lyophilized injectable powder of experimental group, control group and blank group was shone one month under the high light that equal illumination is (4500 ± 500) LX, detect the related substance that Omeprazole Sodium decomposes, the results are shown in Table 2.
The stability of table 2 lyophilized injectable powder under high temperature, high humidity and high light
As seen from Table 2, Sodium Glutamate and sodium tartrate have produced synergy, the acting in conjunction of the two can significantly improve the stability under omeprazole freeze-dried powder injection high temperature, high humidity and the high light, especially when the mass ratio of Sodium Glutamate and sodium tartrate is 8 ~ 10:1, improve more remarkable to the stability of omeprazole freeze-dried powder injection under high temperature, high humidity and high light.
Embodiment 12
1, the untoward reaction of injection liquid test
Experimental group, control group and blank group are set respectively, and the injection liquid that experimental group, control group and blank group adopt is identical with the injection liquid among the embodiment 11.
Select gastric ulcer patient 900 examples, be equally divided at random 9 groups, every group of 50 routine male patient, 50 routine women patients.Adopt respectively the ao meilazole sodium injection liquid of experimental group 1-5, control group 1-3 and blank group that every group of patient carried out intravenous drip, every day 1 time, each 100ml, continuous use 1 month, observe and record the number that every group of patient produces untoward reaction, described untoward reaction refers to feel sick, suffers from diarrhoea, suffers from abdominal pain, at least a in dizziness, headache etc., the results are shown in Table 3.
The untoward reaction test-results of table 3 injection liquid
| Group | The untoward reaction number appears | The ratio that untoward reaction occurs |
| Blank group | 19 people | 19% |
| Control group 1 | 19 people | 19% |
| Control group 2 | 20 people | 20% |
| Control group 3 | 18 people | 18% |
| Experimental group 1 | 18 people | 18% |
| Experimental group 2 | 17 people | 17% |
| Experimental group 3 | 18 people | 18% |
| Experimental group 4 | 4 people | 4% |
| Experimental group 5 | 1 people | 1% |
2, the untoward reaction of lyophilized injectable powder test
Experimental group, control group and blank group are set respectively, and the lyophilized injectable powder that experimental group, control group and blank group adopt is identical with the lyophilized injectable powder among the embodiment 11.
Select patients w ith peptic ulcer disease Disease 900 examples, be equally divided at random 9 groups, every group of 50 routine male patient, 50 routine women patients.Adopt respectively the omeprazole freeze-dried powder injection of experimental group 1-5, control group 1-3 and blank group so that 5% glucose injection 100ml dilution is rear every group of patient to be carried out intravenous drip, every day 1 time, each lyophilized injectable powder that adopts is 60mg, continuous use 1 month, observe and record the number that every group of patient produces untoward reaction, described untoward reaction refers to feel sick, suffers from diarrhoea, suffers from abdominal pain, at least a in dizziness, headache etc., the results are shown in Table 4.
The untoward reaction test-results of table 4 lyophilized injectable powder
| Group | The untoward reaction number appears | The ratio that untoward reaction occurs |
| Blank group | 17 people | 17% |
| Control group 1 | 19 people | 19% |
| Control group 2 | 18 people | 18% |
| Control group 3 | 17 people | 17% |
| Experimental group 1 | 16 people | 16% |
| Experimental group 2 | 17 people | 17% |
| Experimental group 3 | 2 people | 2% |
| Experimental group 4 | 1 people | 1% |
| Experimental group 5 | 3 people | 3% |
Can be found out by table 3 and table 4, when Omeprazole Sodium and Sodium Glutamate, sodium tartrate and ascorbic quality and mass ratio when being 2 ~ 4:1, can significantly reduce the adverse reaction rate of Omeprazole Sodium, especially when Omeprazole Sodium and Sodium Glutamate, sodium tartrate and ascorbic quality and mass ratio when being 3:1, more remarkable to the reduction effect of the adverse reaction rate of Omeprazole Sodium.
Last institute should be noted that; above embodiment is only in order to illustrate technical scheme of the present invention but not limiting the scope of the invention; although with reference to preferred embodiment the present invention has been done detailed description; those of ordinary skill in the art is to be understood that; can make amendment or be equal to replacement technical scheme of the present invention, and not break away from essence and the scope of technical solution of the present invention.
Claims (10)
1. a novel omeprazole sodium compound is characterized in that, the structural formula of described compound is:
Described omeprazole sodium compound adopts following methods to be prepared from: the Omeprazole Sodium crude product is water-soluble, regulate pH value to 6.0 ~ 7.2, the solid that collection is separated out, with the solid that obtains with dissolve with ethanol after, through macroporous adsorbent resin eluent ethyl acetate purifying, collect ethyl acetate and regulate pH for alkaline, collect the solid of separating out, obtain omeprazole sodium compound;
The purity of described omeprazole sodium compound is greater than 99.8%.
2. the pharmaceutical composition of a novel omeprazole sodium compound is characterized in that, described pharmaceutical composition comprises the component of following weight part: 62 ~ 90 parts of Omeprazole Sodiums, 10 ~ 25 parts of Sodium Glutamates, 1 ~ 4 part of sodium tartrate, 7 ~ 12 parts of vitamins Cs.
3. the pharmaceutical composition of novel omeprazole sodium compound as claimed in claim 2 is characterized in that, the mass ratio of described Sodium Glutamate and sodium tartrate is 8 ~ 10:1.
4. the pharmaceutical composition of novel omeprazole sodium compound as claimed in claim 3 is characterized in that, the mass ratio of described Sodium Glutamate and sodium tartrate is 9:1.
5. the pharmaceutical composition of novel omeprazole sodium compound as claimed in claim 4 is characterized in that, described pharmaceutical composition comprises the component of following weight part: 70 parts of Omeprazole Sodiums, 18 parts of Sodium Glutamates, 2 parts of sodium tartrates, 10 parts of vitamins Cs.
6. the pharmaceutical composition of novel omeprazole sodium compound as claimed in claim 2 or claim 3 is characterized in that, described Omeprazole Sodium and Sodium Glutamate, sodium tartrate and ascorbic quality and mass ratio be 2 ~ 4:1.
7. the pharmaceutical composition of novel omeprazole sodium compound as claimed in claim 6 is characterized in that, described Omeprazole Sodium and Sodium Glutamate, sodium tartrate and ascorbic quality and mass ratio be 3:1.
8. the pharmaceutical composition of novel omeprazole sodium compound as claimed in claim 7 is characterized in that, described pharmaceutical composition comprises the component of following weight part: 90 parts of Omeprazole Sodiums, 18 parts of Sodium Glutamates, 2 parts of sodium tartrates, 10 parts of vitamins Cs.
9. the pharmaceutical composition of novel omeprazole sodium compound as claimed in claim 2 is characterized in that, described pharmaceutical composition is injection liquid, lyophilized injectable powder, oral preparations or sprays.
10. the application of novel omeprazole sodium compound as claimed in claim 2 in preparation treatment Gastric Ulcer Treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100348956A CN103059000A (en) | 2013-01-29 | 2013-01-29 | Novel omeprazole compound and pharmaceutical composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100348956A CN103059000A (en) | 2013-01-29 | 2013-01-29 | Novel omeprazole compound and pharmaceutical composition thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103059000A true CN103059000A (en) | 2013-04-24 |
Family
ID=48101929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100348956A Pending CN103059000A (en) | 2013-01-29 | 2013-01-29 | Novel omeprazole compound and pharmaceutical composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103059000A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173375A (en) * | 2014-08-16 | 2014-12-03 | 广州一品红制药有限公司 | Omeprazole-containing composition and application thereof |
| CN109758435A (en) * | 2017-11-09 | 2019-05-17 | 郑州泰丰制药有限公司 | Omeprazole aerosol and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744815A (en) * | 2010-01-12 | 2010-06-23 | 邓学峰 | Composite medicament of omeprazole sodium |
| CN101766614A (en) * | 2010-01-11 | 2010-07-07 | 蔡海德 | Omeprazole sodium combined medicament and preparation method thereof |
| CN102525965A (en) * | 2012-02-24 | 2012-07-04 | 湖北济生医药有限公司 | Omeprazole sodium drug composition and preparation method thereof |
-
2013
- 2013-01-29 CN CN2013100348956A patent/CN103059000A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766614A (en) * | 2010-01-11 | 2010-07-07 | 蔡海德 | Omeprazole sodium combined medicament and preparation method thereof |
| CN101744815A (en) * | 2010-01-12 | 2010-06-23 | 邓学峰 | Composite medicament of omeprazole sodium |
| CN102525965A (en) * | 2012-02-24 | 2012-07-04 | 湖北济生医药有限公司 | Omeprazole sodium drug composition and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104173375A (en) * | 2014-08-16 | 2014-12-03 | 广州一品红制药有限公司 | Omeprazole-containing composition and application thereof |
| CN109758435A (en) * | 2017-11-09 | 2019-05-17 | 郑州泰丰制药有限公司 | Omeprazole aerosol and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512380A (en) | Freeze-dried powder injection with omeprazole sodium as active component and preparation method thereof | |
| CN103285135A (en) | Preparation technology for increasing clarity of poplar flower injection | |
| CN107412440B (en) | Compound red skin blood replenishing oral liquid and quality detection method thereof | |
| CN103058999A (en) | Novel pantoprazole sodium compound and pharmaceutical composition thereof | |
| CN103059000A (en) | Novel omeprazole compound and pharmaceutical composition thereof | |
| CN104687048B (en) | Maca tablet and preparation method thereof | |
| CN113350276A (en) | Preparation method and packaging method of octreotide acetate injection | |
| CN111346061B (en) | Chlorogenic acid composition and preparation method thereof | |
| CN108309944B (en) | Pantoprazole sodium for injection and preparation method thereof | |
| CN109223863B (en) | High-temperature-resistant stomach-soluble type honeysuckle and scutellaria baicalensis dropping pill and preparation method thereof | |
| CN107365272A (en) | A kind of novel imidazole class compound and preparation method thereof and application medically | |
| CN103070834B (en) | Lyophilized powder containing esomeprazole | |
| CN104000778A (en) | Ribavirin injection and preparing method thereof | |
| CN109481459A (en) | A kind of compound electrolyte glucose injection and preparation method thereof | |
| CN103012192B (en) | Novel aceglutamide compound and pharmaceutical composition thereof | |
| CN107595787A (en) | A kind of preparation method of the double meglumine lyophilized formulations of injection Fosaprepitant | |
| CN102757471B (en) | Novel active cytidine disodium triphosphate compound and pharmaceutical composition thereof | |
| CN113303472A (en) | Functional beverage produced by using litsea cubeba and preparation process thereof | |
| CN101491495A (en) | Salvianolic acid B magnesium injection, preparation method and use thereof | |
| CN112679370B (en) | Preparation method of medicinal arginine glutamic acid | |
| CN107137361B (en) | Bone-targeted parecoxib sodium nanocapsule freeze-dried injection and preparation method thereof | |
| CN107556304B (en) | Nitroimidazole medicine and preparation method and application thereof | |
| CN105213326A (en) | A kind of preparation method of clindamycin phosphate for injection lyophilized powder | |
| CN102552180B (en) | Clindamycin phosphate composition liensinine freeze-dried powder and preparation method thereof | |
| CN113845477B (en) | Refining method of pentazocine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130424 |